Native High-Density Lipoprotein and Melatonin Improve Platelet Response Induced by Glycated Lipoproteins
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
30724160
DOI
10.14712/fb2018064040144
PII: file/5879/fb2018a0018.pdf
Knihovny.cz E-resources
- MeSH
- Apoptosis drug effects MeSH
- Aryldialkylphosphatase metabolism MeSH
- Adult MeSH
- Glutathione metabolism MeSH
- Glycosylation drug effects MeSH
- Protein Carbonylation MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoproteins, HDL pharmacology MeSH
- Malondialdehyde metabolism MeSH
- Melatonin pharmacology MeSH
- Nitric Oxide metabolism MeSH
- Oxidation-Reduction MeSH
- Oxidative Stress drug effects MeSH
- Blood Platelets drug effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Aryldialkylphosphatase MeSH
- Glutathione MeSH
- Lipoproteins, HDL MeSH
- Malondialdehyde MeSH
- Melatonin MeSH
- Nitric Oxide MeSH
Activated platelets and glycated lipoproteins are responsible for atherothrombosis in diabetics. Melatonin and native high-density lipoproteins are crucial in the preservation of pro/oxidant-antioxidant balance. The aim of the present study was to investigate the in vitro effects of native high-density lipoproteins and melatonin on altering the platelet response induced by glycated lipoproteins. Low-density lipoproteins and high-density lipoproteins were purified from plasma by ultracentrifugation and were glycated with glucose for three weeks. After incubation with or without melatonin/or native highdensity lipoproteins, low-density lipoproteins, glycated low-density lipoproteins/glycated high-density lipoproteins were added to ADP-induced platelets. Oxidative parameters, caspase-3/9 and nitric oxide levels were measured spectrophotometrically; CD62-P/ annexin-V expression was determined by flow cytometry. In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, platelet malondialdehyde/ protein carbonyl, P-selectin, annexin-V, caspase-3/9 levels were increased (ranging from P < 0.001 to P < 0.01); glutathione and nitric oxide levels were reduced (ranging from P < 0.001 to P < 0.01). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, melatonin treatment reduced malondialdehyde, protein carbonyl, CD62-P, annexin-V and caspase-3/9 (P < 0.001, P < 0.01) levels and elevated nitric oxide (only glycated low-density lipoproteins). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, native high-density lipoprotein treatment reduced malondialdehyde, protein carbonyl, annexin-V, caspase-3/9 levels (P < 0.001, P < 0.01) and increased glutathione; nitric oxide levels (only with gly-HDL). Both melatonin and high-density lipoproteins should be regarded as novel promising mechanism-based potential therapeutic targets to prevent atherothrombosis in diabetics.
Department of Biochemistry Faculty of Pharmacy Marmara University İstanbul Turkey
Department of Biochemistry Medical Faculty Karadeniz Technical University Trabzon Turkey
Department of Immunology School of Medicine Yeditepe University İstanbul Turkey
References provided by Crossref.org